The artificial intelligence (AI)-enabled software, which has a documented 91 percent sensitivity rate for detecting pediatric fractures, is reportedly the first AI fracture detection modality to receive FDA 510(k) clearance for use in the pediatric population.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the use of BoneView (Gleamer), an artificial intelligence (AI) software that helps detect fractures on X-ray, in patients over two years of age.1
In a recently published study involving 300 pediatric patients, researchers demonstrated a 91.3 percent sensitivity rate and a 90 percent sensitivity rate for fracture detection.2
Christian Allouche, the chief executive officer of Gleamer, called the pediatric clearance a significant advance in the company’s efforts to improve fracture detection and diagnosis through the use of AI.1
Employing deep learning algorithms, the BoneView software analyzes X-rays and highlights regions of interest for suspected fractures that are sent to the radiologist for confirmation, according to Gleamer. The company said BoneView is the only AI fracture detection software to have FDA clearance for use in adults and pediatric patients.
The FDA initially granted BoneView 510(k) clearance in March 2022 for fracture detection in adults.3
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.